Search results for "Complete"

showing 10 items of 490 documents

Are There Essentially Incomplete Knowledge Representation Systems?

2001

A mathematical model of a knowledge representation system (KR-system) is proposed. Its prototype is the concept of an information system in the sense of Z. Pawlak; however, the model is, in fact, a substantial extension of the latter. In our model, attributes may form an arbitrary category, where morphisms represent built-in functional dependencies, and uncertainty of knowledge is treated in terms of category theory via monads. Several notions of simulation are also considered for such KR-systems. In this general setting, the semiphilosophical problem mentioned in the title, still open, is given a precise meaning.

MorphismTheoretical computer scienceKnowledge representation and reasoningComplete informationComputer scienceMathematics::Category TheoryFuzzy setInformation systemCalculusRepresentation (systemics)Extension (predicate logic)Category theoryFunctional dependency
researchProduct

Consistency Analysis of Genome-Scale Models of Bacterial Metabolism: A Metamodel Approach.

2015

Genome-scale metabolic models usually contain inconsistencies that manifest as blocked reactions and gap metabolites. With the purpose to detect recurrent inconsistencies in metabolic models, a large-scale analysis was performed using a previously published dataset of 130 genome-scale models. The results showed that a large number of reactions (~22%) are blocked in all the models where they are present. To unravel the nature of such inconsistencies a metamodel was construed by joining the 130 models in a single network. This metamodel was manually curated using the unconnected modules approach, and then, it was used as a reference network to perform a gap-filling on each individual genome-s…

MultidisciplinaryConsistency analysisBacteriaProcess (engineering)lcsh:RGenome scalelcsh:MedicineBiologycomputer.software_genreBioinformaticsModels BiologicalMetamodelingSet (abstract data type)Consistency (database systems)Bacterial ProteinsProof of conceptlcsh:QData miningMetagenomicsCompleteness (statistics)lcsh:SciencecomputerGenome BacterialMetabolic Networks and PathwaysResearch ArticlePLoS ONE
researchProduct

Kinerja Sapi Bali Jantan yang diberikan pakan Rumput Gajah (Punnisetum purpureum) subtitusi fermentasi Jerami Padi

2018

The research was aimed to study Bali bulls fed with Pennisetum purpureum with fermented rice straws substitution in Manokwari Regency, West Papua was conducted experimentally with 12 Bali bulls that have average weight of 176.02±38.35 kg with 2 – 2,5 years old for 5 months duration. The study was designed using complete randomized design of nested pattern with 3 (three) treatments, 4 (four) replications and 4 (four) times weighing, with an assumption that Bali bulls are nested during weighing time. The results of this study showed that Penicetum purpureum substitution with fermented straws did not significant on Bali bulls body weight. The duration of fermented rice straws feeding that subs…

Nested PatternAnimal sciencemedicineGeneral MedicineRice strawPennisetum purpureummedicine.symptomBiologybiology.organism_classificationBody weightWeight gainCompletely randomized designBali cattleCassowary
researchProduct

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

THE MAXWELL–DIRAC EQUATIONS: ASYMPTOTIC COMPLETENESS AND THE INFRARED PROBLEM

1994

In this article we present an announcement of results concerning: a) A solution to the Cauchy problem for the M-D equations, namely global existence, for small initial data at t = 0, of solutions for the M-D equations. b) Arguments from which asymptotic completeness for the M-D equations follows. c) Cohomological interpretation of the results in the spirit of nonlinear representation theory and its connection to the infrared tail of the electron in M-D classical field theory. The full detailed results will be published elsewhere.

Nonlinear systemCompleteness (order theory)Mathematical analysisDirac (software)Initial value problemClassical field theoryStatistical and Nonlinear PhysicsRepresentation theoryMathematical PhysicsMathematicsInterpretation (model theory)Mathematical physicsConnection (mathematics)Reviews in Mathematical Physics
researchProduct

Correcting for Potential Barriers in Quantum Walk Search

2015

A randomly walking quantum particle searches in Grover's $\Theta(\sqrt{N})$ iterations for a marked vertex on the complete graph of $N$ vertices by repeatedly querying an oracle that flips the amplitude at the marked vertex, scattering by a "coin" flip, and hopping. Physically, however, potential energy barriers can hinder the hop and cause the search to fail, even when the amplitude of not hopping decreases with $N$. We correct for these errors by interpreting the quantum walk search as an amplitude amplification algorithm and modifying the phases applied by the coin flip and oracle such that the amplification recovers the $\Theta(\sqrt{N})$ runtime.

Nuclear and High Energy PhysicsQuantum PhysicsTheoryofComputation_COMPUTATIONBYABSTRACTDEVICESComplete graphGeneral Physics and AstronomyFOS: Physical sciencesTheoryofComputation_GENERALStatistical and Nonlinear PhysicsOracleTheoretical Computer ScienceVertex (geometry)CombinatoricsAmplitudeComputational Theory and MathematicsAmplitude amplificationTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITYGrover's algorithmQuantum algorithmQuantum walkQuantum Physics (quant-ph)Mathematical PhysicsMathematicsMathematicsofComputing_DISCRETEMATHEMATICS
researchProduct

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

2021

PETHEMA/GEM Cooperative Group.

OncologyAdultBoron CompoundsMalemedicine.medical_specialtyNeoplasm ResidualPhysics::Instrumentation and DetectorsClinical Trials and ObservationsImmunologyPatient subgroupsGlycineDrug resistanceBiochemistryDexamethasoneBortezomibhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmHumansProgression-free survivalTreatment resistanceLenalidomideComplete responseMultiple myelomaAgedChromosome AberrationsLymphoid Neoplasiabusiness.industryCell BiologyHematologyMiddle Agedmedicine.diseaseFlow CytometryProgression-Free Survivalbody regionsClinical trialTreatment OutcomeDrug Resistance NeoplasmFemalebusinessMultiple Myeloma
researchProduct

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…

2021

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…

OncologyCPS combined positive scoreTC tumor cellsICI immune checkpoint inhibitorTriple Negative Breast NeoplasmsB7-H1 AntigenMedicineHER2 human epidermal growth factor receptor 2Triple-negative breast cancerRC254-282ICC intraclass correlation coefficientbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMSI microsatellite instabilityImmunohistochemistrypCR pathological complete responsePFS progression-free survivalImmunohistochemistryOriginal ArticleIC-ScoreIC immune cellsIHC immunohistochemistryProgrammed deathPD-L1medicine.medical_specialtyConcordanceTNBC triple-negative breast cancerOS overall survivalBreast cancerTriple-negative breast cancerPD-L1Internal medicineTPS tumor proportion scoreBiomarkers TumorHumansProgrammed death-ligand 1Reproducibilitybusiness.industryReproducibility of Resultsmedicine.diseaseITT intention to treatCI confidence intervalPD-L1 programmed death-ligand 1biology.proteinSurgeryCPSbusinessKappaTMB tumor mutational burdenBreast
researchProduct

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma

2020

Despite advances in standards of care, the prognosis of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains poor. In these patients, 50–74% fail to respond to next line therapy,...

OncologyCancer Researchmedicine.medical_specialty03 medical and health sciences0302 clinical medicineRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicineAntibodies BispecificmedicineHumansComplete responsebusiness.industryLymphoma Non-HodgkinHematologymedicine.diseaseLymphomaOncology030220 oncology & carcinogenesisRelapsed refractoryBlinatumomabLymphoma Large B-Cell DiffuseNeoplasm Recurrence LocalbusinessDiffuse large B-cell lymphoma030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.

2019

e19041 Background: Achieving durable response in patients (pts) with relapsed/refractory (R/R) aggressive B-cell lymphoma (B-NHL) is challenging. Blinatumomab, a bispecific T-cell engager (BiTE) immunotherapy targeting CD19-expressing cancer cells, has shown promising efficacy in pts with R/R aggressive B-NHL. We report the durability of complete response (DOCR) in pts treated with blinatumomab. Methods: The DOCR in pts with R/R aggressive B-NHL responding to blinatumomab was assessed using data from two phase 2 studies (study 1 [N = 25], NCT01741792; study 2 [N = 41], NCT02910063) in pts with R/R aggressive B-NHL. CR was assessed using Cheson (study 1) and Lugano (study 2) criteria. Time-…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseaseLymphomaOncologyRefractoryimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineB-Cell Non-Hodgkin LymphomaBlinatumomabIn patientbusinessComplete responsemedicine.drugJournal of Clinical Oncology
researchProduct